Home
WHO India
Core Programme Clusters
Communicable Diseases and Disease Surveillance (CDS)
Health Systems Development (HSD)
Family & Community Health (FCH)
Non Communicable Diseases & Mental Health (NMH)
Sustainable Development & Healthy Environment (SDE)
Information Services
Links
WHO Collaborating Centers
Training Grants/ Fellowships/ Call for Proposals
Vacancy
What’s New
Review of Studies on Financing of Drugs & Pharmaceuticals in India
Annotated Bibliography
Sr.
Title
Author
Source of Publication
Year of Publication
Type of Paper
1.
GSK goes to SC over Drug Price Controls
The Economic Times
2004
News
2.
Huge Investments in Pharma Sector May Hike Drug Prices
Ashok B Sharma and
BV Mahalakshmi
The Financial Express
News Paper Article
3.
India to Extend Price Control on Drugs
Sanjay Kumar
British Medical Journal
News Article
4.
Indian patients go to Court over Cancer Drugs
Ganapati Murdur
5.
Irrational Prescriptions
Economic and Political Weekly
2003
Editorial
6.
Projecting Drug Expenditures 2003
Nilay D. Shah
American Journal of Health System Pharmacy
Article
7.
Profiteering in Medicines
Anant Phadke
Letter to the Editor
8.
Indian Pharma Cos to get Greater Access to the US Market
Monthly Commentary on India Economic Conditions
Commentary
9.
10th Plan for Independent Pharma Regulatory Authority
Amiti Sen
10.
Benefits of WTO Drug Agreement for Poorer Nations
Journal of Intellectual Property Rights
11.
Interpreting Para 6 Deals on Patent and Access to Drugs
K Ravi Srinivas
12.
Have Drug Prices Fallen?
Wishvas Rane
13.
The Political Economy of Drug Quality. Changing Perceptions and Implications for Indian Pharmaceutical Industry
Amit S Ray, Saradindu Bhaduri
14.
Indian Pharmaceutical Industry in WTO Regime A SWOT Analysis
N Lalitha
2002
15.
Projecting Drug Expenditures 2002
Shah ND et al
16.
Does India have a Competitive advantage in Pharma
Anirudh Gopala Krishnan
Indian Management
17.
How Stronger Patent Protection in India might affect the Behavior of Transnational Pharmaceutical Industries
Fink Carsten
18.
New Drug Policy: Savage Attack on People's Health
Amit Sen Gupta
Peoples Democracy
19.
TRIPS and Parallel Imports: Impact on Drug Prices
MD Nair
20.
Drug Policy 2002 Prescription for Symptoms
21.
Pharmaceutical Policy 2001: Industry Wish-List
22.
A Study on Availability and Prices of Medicines in India
Bejon Misra
Voluntary Organization in Interest of Consumer Education (VOICE)
Report
23.
Prices of Prescription Drugs. Marginal Rise in Cardiovascular Products
24.
Raising Drug Prices and Public Health
Monthly Commentary on Indian Economic Conditions
25.
Drug Price Control: Who is in Charge?
S Srinivasan
2001
26.
Projecting Future Drug Expenditures-2001
Mehl B
27.
The Economics of Prescription Drug Pricing
Michael Doonan
Background Paper, Council on the Economic Impact of Health System Change
Background Paper
28.
Consumption and Trade in Off-Patented Medicines
Harvey E Bale
Working Paper-65, Indian Council for Research on International Economic Relations
Working Paper
29.
Differentiated Pricing of Patented Products
John Barton
Working Paper-63
30.
Post Trips Options for Access to Patented Medicines in Developing Countries
FM Scherer and Jayashree Watal
Working Paper-62
31.
Wastage of Irrational Drug Use
Yojana
Book Review
32.
TRIPS Product Patents and Pharmaceuticals
Veena Mishra
Viewpoint
33.
Decontrol of Drug Prices
34.
TRIPS and India's Pharmaceutical Industry
Pradeep Agrawal, P Saibaba
Review Article
35.
The New Drug Policy: Towards Rational Use
N Devadasan
36.
Drug Supply and Use: Towards a Rational Policy in India
Seminar
2000
37.
Title: How WTO/TRIPS Threatens the Indian Pharmaceutical Industry
Richard Gerster
Third World Network
38.
End of Drug Control
39.
Projecting Future Drug Expenditures-2000
40.
Pharmaceuticals, WTO and Seattle Round
41.
A Visit to India: Drug Prices, Research, and Global Access
David Scondras
Peoples Health Movement
1999
42.
Continuing Rise in Drug Prices: Brand Leaders Show the Way
43.
How Many Aspirins to One Rupee? Runaway Drug Prices
S. Srinivasan
44.
Indian Patents Act (Amendment) Bill may Affect Profitability of Pharmaceutical Industry
